

ISICR Officers

President

Keiko Ozato

President-Elect

Howard Young

Secretary

Sidney Pestka

Treasurer

Sam Baron

Future ISICR Meetings

Oct. 6 - 11, 2002

Torino, Italy

Joint ISICR/ICS/SLB/ECS

www.marionegri.it/cyto2002/

•

Oct. 26 - 30, 2003

Cairns, Australia

•

Oct. 21-25, 2004

San Juan, Puerto Rico

(Joint with ICS)

ISICR WWW Site

www.ISICR.org

ISICR Business Office

ISICR@faseb.org

TEL: 301-571-8319

FAX: 301-530-7049

ISICR Newsletter Editors

Howard Young

youngh@mail.ncifcrf.gov

Fax: 301-846-1673

Pat Fitzgerald-Bocarsly

Bocarsly@umdnj.edu

Fax: 973-972-7293

Hannah Nguyen

nguyenh@methylgene.com

Seng-Lai (Thomas) Tan

tan_seng-lai@lilly.com

Tel: 317-277-2626



April 2002
Volume 9, No. 2

A message from the ISICR president

Keiko Ozato

Personal reflection

Almost twenty years ago I ventured into the field of interferon /cytokine and became an ISICR member. I was a struggling, “wannabe” tenured scientist at NIH. I knew hardly anybody in the field, but was attracted to interferon research because of my interests in the mechanism of interferon action. My initial interests focused on how both type I and type II interferons induced major histocompatibility molecules, as this was my first project as an independent researcher. So, I applied for an ISICR Travel Award, despite being told by “wise men around NIH” that these things are usually political, and since I do not have a boss, or friends in the society, I wouldn’t have a chance. To my surprise, I received a travel award and this gift was enlightening and very precious to me.



Keiko Ozato

This humble, personal story epitomizes the fundamental tenet of the society, i.e., the pursuit of excellence in science and the spirit of fellowship among members. I believe that it is this spirit by which I am given the privilege of serving as the first Asian female President of the Society. I begin my presidency with the renewed sense of awareness about our basic tenet. The ISICR is not just a transient, random assembly of scientists in the field; it is a community where each member represents a critical building block. In an historical perspective, while we are in a temporary stage when two international societies with very similar scientific goals co-exist, I think that it is the tradition of community spirit that provides the ISICR with its unique identity and strength.

A Sound Research Community and Excellence in Science: The Milstein Awards.

A sound research community can produce high quality science. The Milstein Awards have been the symbol of excellence in our field for many years. With the Awards we celebrate fellow researchers’ achievements and appreciate our own work in the field. Our society has been blessed with the support of the Milstein Family Foundation, which has provided the forum for recognizing excellence in Interferon research. Mr. Seymour Milstein’s passing in the past year greatly saddened the Society membership and left some doubt as to the future of these prestigious awards. I can now report that Dr. Sidney Pestka, our liason to the Foundation, has informed me that the Milstein Foundation will continue to support the Milstein Awards in 2002. We are deeply indebted to the Milstein Foundation for continuing to recognize outstanding research in

Continued on page 4

2002 ISICR AWARDS

The ISICR Awards Committee invites nominations for 2002 Milstein Awards, the Christina Fleischmann Award, the Young Investigator Awards, and Honorary Membership. The deadline for the nominations is May 18, 2002.



The Milstein Award

Individuals who have made exceptional contributions to research related to interferons and cytokines either in a basic or clinical field. Milstein awards are made possible by the generous gift of Mrs. Seymour Milstein and family through the Milstein Foundation. This award represents a pinnacle of scientific achievement in our field and is an important landmark of the society

Honorary Membership

Nominees should be individuals who have made substantive contributions to the interferon/cytokine field over much of their careers, either in basic, clinical or applied research. Honorary members are the treasure of the society who provide us with an historical perspective and valued research tradition. We invite your nominations for eligible candidates for prestigious symbols of recognition by our society for outstanding achievements. A brief exposition of the basis for your nomination and other supportive documents (such as CV, if available) should be sent to the ISICR President:

Dr. Keiko Ozato
National Institutes of Health
LMGR/NICHD
Bldg 6 Rm 2A01
Bethesda, MD 20892
FAX: 301-480-935; E-mail: ozatok@dir6.nichd.nih.gov

The nominations will be collated, and passed on to the Chair of the Awards Committee in May. This committee will then prepare a short list of candidates and vote for winners of the awards. As specified in the ISICR Constitution, the final vote of the Awards Committee is subject to the approval of the ISICR Board of Directors.

Young Investigator Awards (\$1,000)

Eligibility: ISICR members and are less than 8 years after receiving a Ph.D or M.D degree. Every year up to five Young Investigator Awards are presented to ISICR members who have made notable contributions to either basic or clinical research within 8 years after receiving their Ph.D or M.D.. This award is provided by a generous gift of the Milstein Foundation. We urge every eligible individual to apply for the awards. We also ask more senior laboratory advisers to encourage their associates to apply. Send your 2001 Meeting abstract and CV to:

Dr. Paula Pitha-Rowe,
Chair, ISICR Awards Committee
Johns Hopkins University
Dept. of Oncology
1650 Orleans Street, Rm 221
Baltimore, MD 21206
FAX: 410-955-0840; Email: parowe@jhmi.edu

We plan on having a check-off box in the abstract form for easy identification of the eligible candidates. A brief note describing your accomplishments and a letter of recommendation from your adviser, are strongly encouraged. The deadline is the same as that of the Meeting abstract for the 2002 ISICR Meeting.

The Christina Fleischmann Memorial Award to Young Women Investigators (\$1,000)

The rules for this ISICR award are the same as for the Milstein Young Investigator Award (see above) except for gender and that candidates are less than 10 years after receiving a PhD or M.D. degree.

Travel Awards

ISICR members who intend to attend the 2002 ISICR meeting in Torino, Italy are eligible for Travel Awards. They are provided primarily through the membership fees, based on the scientific merit of the abstract and financial necessity. However, this award does not exempt payment of the registration fee. Please note that there are no age restrictions to this award. However if both senior and junior members from the same laboratory apply for an award, preference will be given to the junior member. Send your meeting abstract and a note explaining the need for a Travel Award to Dr. Paula Pitha-Rowe, Chair, ISICR Awards Committee (the deadline is the same as that of the Meeting abstract, May 18).

New ISICR Members

The ISICR welcomes the following new members to the society.

We look forward to their active participation in the Annual Meeting and on those ISICR committees that they wish to serve. (Please contact ISICR President Dr. Keiko Ozato regarding committee membership. Volunteers are always welcome and needed!!!!).

Diana Brassard
Union, NJ

Merike Kelve
Tallinn, Estonia

Youcun Qian
Cleveland, OH

Silvia Bulfone-Paus
Borstel, Germany

Toby Lawrence
La Jolla, CA

Michael E. Sanford
Frederick, MD

**Tatiana V.
Chernovskaya**
Lyubuchang, Russia

Bonnet Marlon
Paris, France

Caroline Sawe
Everett, WA

Annalisa D'Andrea
Menlo Park, CA

Thomas Michiels
Brussels, Belgium

Barbara Sherry
Manhasset, NY

Austin L. Gurney
South San Francisco, CA

Kathrin Muegge
Frederick, MD

Lorelie H. Villarete
Alameda, CA

Pamela Hebert
Shreveport, LA

Yoshihiro Muneta
Tsukuba Ibaraki, Japan

Donghua Wang
Baltimore, MD

Ulrich Kalinke
Langen, Germany

**Evangelos I.
Ntrivalas**
North Chicago, IL

Frank Zaldivae
Orange, CA

Yuka Kanno
Bethesda, MD

Soren Riis Paludan
Aarhosc, Denmark

Keiko Ozato, *from page 1*

the field of Interferon research.

Global membership

Science has no national boundaries, nor does the ISICR: our members are from all over the world. Also, many members have active international collaborations. Nevertheless, in terms of proportion to the research activity, our society has fewer European and Asian members than it could/should have on its membership roles. I would like to ask your help in increasing our membership not only in North America, but also in these important areas of the world. We must also extend our efforts to recruit new members from “scientifically emerging” countries such as China, Eastern Europe, and South America where researchers in the field are at last establishing scientific careers in their own environment. Indeed, over the years the ISICR has supported researchers from some of developing countries in a small way by awarding of travel awards to the annual meeting. In addition, some countries have come a long way to launch a research community of their own and to successfully hold a meeting focused on interferons (e.g. the Cuban international meeting in 2001). We must continue to reach out and support their efforts. I expect that the upcoming Annual Meetings in Australia and China will provide us with the opportunities for increasing the international globalization of our scientific community.

2002 Annual Meeting

In October this year we will join the International Cytokine Society, the Society for Leukocyte Biology and the European Cytokine Society for our annual meeting in Torino, Italy. Dr. Santo Landolfo is leading the ISICR effort in organizing an exceptional meeting and preparations are well under way. This meeting is a good opportunity for ISICR members to present their

work and to learn of new developments in the field of interferon/cytokine biology. I urge you to attend the Meeting and take advantage of the opportunity to meet and interact with scientists with diverse backgrounds and expertise. As before, the Awards committee will be working hard to provide Travel Awards to many members; these awards are “an envy” of other societies. Visit the ISICR web site for information and look for the forthcoming announcement in the mail.

Publication in the JICR

The JICR is our official society journal. The Publication Committee headed by Dr. Bob Fleischmann and the Editorial Board of the journal have made enormous efforts in enhancing the quality of the journal and increasing subscriptions. Publication of reviews on specific topics have been a success in attracting readership. Given the rapid progress in interferon/cytokine biology in both the basic and clinical arenas, JICR has the potential to further improve its quality and standing in the scientific community. I encourage you to publish your high quality work in the JICR. When market-based publishers dominate and influence our choice of journals by factors other than science itself, a journal published under the auspices of working scientists can offer an alternative way of spreading information and is worthy of support. In addition, an effort is being made to explore a wider access to the journal through on-line subscription and on-line publication.

ISICR Newsletter and List Serve

Active communication among members is an integral part of a healthy research community. The ISICR newsletter has been a significant benefit for our society by providing useful information quickly. Note that none of the other societies participating in the Torino meeting have an equivalent publication. As it

enters its 9th year, Howard Young and his dedicated editors, all of whom serve on a volunteer basis, are to be thanked for the continual, timely publication of the Newsletter.

The ISICR will soon have an additional means of informal, open communication within the membership, through a Web based Email ListServe. Delores Francis and George Galasso at FASEB are working on establishing this method of communication for the ISICR. Upon completion, we will have an e-mail system providing instant access to the ISICR membership, to and from any corners of the globe. With this service we can ask for (and give) any kind of scientific advice and it can serve to help members locate specific reagents.

I believe that the future of our society is bright but does depends upon the active participation of our members. Bring your colleagues into society membership and participate yourself. I know that you will find it worthwhile.

Keiko Ozato

Famous Quotes

“In order that people may be happy in their work, these three things are needed: they must be fit for it; they must not do too much of it; and they must have a sense of success in it.”

—John Ruskin,
author, art critic,
and social reformer
(1819-1900)

“Persistence is what makes the impossible possible, the possible likely, and the likely definite.”

—Robert Half

“If you are not living on the edge, you are taking up too much room.”

—Jayne Howard

Fighting bioterrorism: IFN to the rescue? By Thomas Tan

Following the events of September 11, 2001 and the use of *Bacillus anthracis* as a bioweapon of mass destruction, there is now alarming concern that other biological agents may be similarly used. A recent bioterrorism exercise, *Dark Winter*, built around a scenario of a bioterrorist attack based on the intentional release of variola virus has painted a frightening picture of our vulnerability to the actions of biological terrorism (<http://www.homelandsecurity.org/darkwinter/index.cfm>), further heightening the importance of appropriate preparedness in the face of a large-scale bioterrorist act.

Our scientific, medical and pharmaceutical communities have been called upon to meet these threats by increasing the production of available vaccines, antibiotics, antiviral drugs, and diagnostic kits, and identifying new ones against potentially deadly biological agents that could be used against civilians and military. Ideally, the remedies should possess broad-spectrum anti-microbial activity as the terrorists would likely use or engineer strains that are resistant to multiple drugs.

Amarillo Biosciences, Inc. (ABI) is poised for such an effort. The biotechnology company is testing the use of low-dose oral interferon-alpha (IFN- α) as a broad-spectrum immune modulator defense against some bioweapons. Low-dose oral IFN- α has been shown to significantly reduce the number of vaccinia virus (vv) pocks on the tails of mice model (Nagao et al. Oral-mucosal administration of IFN-alpha potentiates immune response in mice *J. Interferon Cytokine Res.* 18: 661-666, 1998). Oral doses of 1, 10 or 100 IU of murine IFN- α were as effective as injections of arabinofuranosyl adenosine in decreasing vv pocks.

"Because of its low cost, ease of administration, established safety, room-temperature stability and efficacy in numerous studies, we believe orally-administered IFN- α deserves consideration as the first line of defense against some bioweapons," Dr. Joseph Cummins, President and CEO of ABI.


According to Dr. Cummins, the National Institutes of Allergy and Infectious Diseases (NIAID) has assigned an ARB number so testing of low-dose oral IFN- α can begin in NIAID-sponsored research in mice models of small pox (cow pox and vaccinia). In addition, a company specializing in biodefense is testing orally administered IFN- α in mouse models of anthrax and Venezuelan equine encephalitis (VEE) virus.

Because of concern about foot-and-mouth disease (FMD), ABI is urging consideration of a new response to the possible introduction of FMD virus into the USA. Currently, if FMD arrives, the USDA is poised to depopulate livestock, just as was done in the UK where 4,078,000 animals were killed in 2001 (www.defra.gov.uk/footandmouth/cases/statistics/generalstats.asp). In response to terrorist attacks with FMD virus in the USA, however, an alternative response to depopulation must be considered. Eradication of FMD in the USA will cost at least \$30 billion (Williams JL and Sheesley D. Response to Bio-terrorism directed against animals. *Ann N Y Acad Sci* 916:117-120, 2000).

The FMD virus has evolved a strategy to defeat the host cell defenses. The FMD virus 1) inhibits IFN- α / β production (Chinsangaram J, Piccone ME, et al. Ability of foot-and-mouth virus to form plaques in cell culture is associated with suppression of alpha/beta interferon. *J Virol* 73(12):9891-9898), and 2) blocks double-stranded RNA-dependent protein kinase R (PKR), a key IFN-inducible antiviral pathway (Chinsangaram J, Koster M, et al. Inhibition of L-depleted foot-and-mouth disease virus replication by alpha/beta interferon involved double stranded RNA-dependent protein kinase. *J Virol* 75(12):5498-5503, 2001). It is reported that orally-administered IFN- α upregulates two other IFN-inducible antiviral pathways (Mx protein (Brod SA, Nelson L, et al. Ingested interferon alpha induces Mx RNA. *Cytokine* 11(7):492-499, 1999) and 2' 5' adenylate synthetase (Takayama S, Iwaki K, et al. Effects of oral administration of interferon-a on antibody production in mice with induced tolerance. *J Interferon Cytokine Res* 19(8):895-900, 1999). ABI is testing cattle to determine if oral IFN- α will upregulate PKR and restore host cell defenses against FMD virus. ABI is proposing that oral IFN- α be used for short-term immune modulation while FMD virus vaccination is used for long-term immunity.

The low-dose, oral IFN- α technology recommended is supported by scientific evidence and is an attractive economical alternative to slaughter of livestock with FMD. The draft USDA plan to deal with FMD will be difficult to implement if terrorists attack at multiple sites. Depopulation and burial in a trench "at least 7 feet wide and 9 feet deep" will be extremely expensive and difficult.

While the therapeutic efficacy of orally administered IFN has not been firmly established, in the December 2001 issue of the *Journal of Interferon & Cytokine Research*, there were three publications regarding orally administered IFN- α . A publication by Pei, et al. reported that oral chicken IFN- α inhibited infectious bronchitis virus replication and reduce the severity of symptoms in chickens. A publication by Meritet, et al. reported that oromucosal human IFN- α or IFN- β given once a day for a week induced tolerance 28 days after subcutaneous human IFN- α or IFN- β . A publication by Brod, et al. reported that "ingested" human IFN-a preserved residual B-cell function in Type 1 diabetic patients.

In a related study, conducted by Dr. John F. Anderson (Connecticut Agricultural Experiment Station) and Dr. James J. Rahal (New York Hospital Queens and Weill College of Medicine, Cornell University) IFN- α was found to be both protective and therapeutic against West Nile Virus, at least in a cell culture system (Anderson JF and Rahal JJ. Efficacy of interferon alpha-2b and ribavirin against West Nile Virus in vitro. *Emerging Infectious Diseases* 8(1): 107-108, 2002). Encouraged by the results, these groups are planning to test IFN- α against other mosquito carried viruses. But whether these results can be validated in relevant animal models remain to be seen. 

JICR News

This month the Journal of Interferon and Cytokine undergoes signal changes in its Editorial Board.

Lawrence B. Lachman, the Editor-in-Chief of the Cytokine Section is stepping down after providing yeoman service in that position since the inception of the Journal in 1995 that brought together two bimonthly publications, Journal of Interferon Research and Lymphokine and Cytokine Research, the latter founded by Larry in 1981 and stewarded by him before the merging of the two journals

The position Editor-in-Chief of the Cytokine Section will pass into the able hands of Thomas A. Hamilton of the Cleveland Clinic. Tom joins us with the enthusiastic endorsement of the Section Editors of the Journal and the Publications Committee of the International Society of Interferon and Cytokine Research, and its able chair W. Robert Fleischmann. Tom Hamilton brings to the Journal an international reputation as a leader in the field of cytokine research and an enthusiasm to further enhance the quality of the Journal.

Two Section Editors have resigned after a long and distinguished service. Norman B. Finter, Section Editor, Interferon Biology, is a pioneer in interferon research and

we have been extremely fortunate to have his services from the inception of the Journal in 1980. Anyone subjected to Norman's editorial pen will acknowledge his skill in being able to reduce the size of an abstract by a factor of two without sacrificing any of its scientific content, while improving its readability. A rare talent that we will sorely miss. We wish Norman a well-earned retirement.

Michael Aguet has served admirably as Section Editor, Interferon Receptors, for the past 7 years, assuming that position when the two journals merged. His activities in a major institution have drawn him away from the interferon field where his scientific prowess made him an astute Section Editor, practicing the highest of editorial standards.


Two new Section Editors have been appointed to represent emerging areas of research in interferon and cytokines. Peter Staeheli will handle manuscripts that relate to avian interferon and cytokines, and Michael G. Tovey those that relate to oromucosal cytokine interactions. Peter's recent review (JICR 21:993-1010, 2001) and Michael's plethora of papers on oromucosal cytokine interactions, along with the Special Topics Issue on the Oral Use of Interferons and Cytokines (JICR

19:813-979, 1999) insure the Journal a leading position in reporting the rapid growth of these two exciting areas of research. Lastly, I am pleased to announce that Anthony Meager will head a new Section, Reviews, designed to encourage the submission of timely reviews of interest to the interferon and cytokine community.

Sincerest appreciation for the dedicated service of the following members rotated off the Editorial Board: Christine W. Czarniecki, Michael A. Horisberger, Hans Strander, Jun Utsumi, and Juana Wietzerbin.

Finally, the masthead of the February 2002 issue includes the names of seven new Editorial Board members whose services will be appreciated over the next three years in their role as reviewers, if not contributors, two critical activities that assure the quality of the Journal: Mariano Esteban, Graham R. Foster, Takashi Fujita, Ilkka Julkunen, Bernd Kaspers, John M. Kirkwood, and Margaret J. Sekellick.

Philip I. Marcus
Editor-in-Chief, Interferons

Newsletter Editor's Note: Check out the Jan. 2002 issue of the JICR. It's entirely devoted to articles on Interferon Regulatory Factors!!! 

NEW FEATURE: Partnerships

Are you looking for partners to help with your research or to have a new product tested in basic research labs? The ISICR newsletter will now include a new feature on "Partnerships". Any Academic, Government or Commercial organization that is looking for research partners is encouraged to send us a description of the type of partnerships desired. Those descriptions deemed suitable for the newsletter will be included in the upcoming issue. Note that we will not include fee for service requests nor will we post advertisements of company products.

Clinical Trials

Study ID Number: 94-I-0073.
Recruitment of Peripheral Blood Hematopoietic Progenitors by **Granulocyte Colony Stimulating Factor**. National Institute of Allergy and Infectious Diseases, Bethesda, MD. Contact: Patient Recruitment and Public Liaison Office
Tel: 1-800-411-1222
Email: prpl@mail.cc.nih.gov

Study ID Numbers NCCR-M01RR02558-0120. Prevention of cognitive decline in Alzheimer's disease by ingested **Interferon Alpha**. Contact: Staley A. Brod, M.D. Texas University of Texas - Houston, Gerontology Center of the UTMSI, Houston, TX Tel: 713-500-7046
Email: staley.a.brod@uth.tmc.edu

Study ID Numbers 010249; 01-DK-0249 **Interferon-Alpha** for Diabetes Mellitus Type 1. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. Contact: Patient Recruitment and Public Liaison Office.
Tel: 1-800-411-1222
Email: prpl@mail.cc.nih.gov.

Study ID Numbers 199/15216; NYU-9938; NCI-101. Thalidomide Plus **Interferon Alfa** in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed. Contact: Jonathan Schwartz, Mount Sinai School of Medicine, New York, New York
Tel: 212-241-3984; Franco M. Muggia, NYU School of Medicine's Kaplan Comprehensive Cancer Center New York, New York
Tel: 212-263-6485

Study ID Numbers 199/13409; EORTC-30955; MRC-RE04. **Interferon Alfa** With or Without **Interleukin-2** and Fluorouracil in Treating Patients With Kidney. Study Chair Martin Eric Gore, Chair Cancer Research Campaign Clinical

Trials Unit- Glasgow Tel: 0141-211-2835; Pieter H.M. de Mulder, Chair EORTC Genito-Urinary Tract Cancer Group Tel: 31-24-361-11-11; Peter John Selby, Chair Medical Research Council Clinical Trials Unit, Tel: 113 242 98 83

Study ID Numbers C-1502; 0101-453. Dose Escalation Study to Determine the Safety of **IFN-Beta** Gene Transfer in the Treatment of Glioblastoma Multiforme. Contact: Katie L. Walsh
Tel: 1-800-824-6436 x2670
Email: Katie_Walsh@biogen.com
Jima H. Deyab
Tel: 1-800-824-6436 x3234
Email: Jima_Deyab@biogen.com

Study ID Numbers 199/12934; MDA-ID-96253; NCI-T96-0106. Phase I Study of Intraperitoneal Autologous Therapeutic Tumor Vaccine AUT-OV-ALVAC-hB7.1 and **Interferon Gamma** in Patients with Refractory Ovarian Epithelial Cancer. Contact: Ralph S. Freedman, Chair, University of Texas - MD Anderson Cancer Center.
Tel: 713-792-2764

Study ID Number: 94-I-0149. Treatment of Multiple Drug Resistant Tuberculosis with **Interferon Gamma**: A Phase I/II Dose Escalation Trial. National Institute of Allergy and Infectious Diseases, Bethesda, MD. Contact: Patient Recruitment and Public Liaison Office Tel: 1-800-411-1222 Email: prpl@mail.cc.nih.gov

Study ID Numbers 199/11274; CNR-9506; EU-95024. Surgery and Radiation Therapy With or Without **Interleukin-2** in Treating Patients With Cancer of the Mouth or Oropharynx. Contact: Giorgio Cortesina, Chair European Institute of Oncology - Chemo Prevention
Tel: 39-011-663-1216

Study ID Numbers AIEDRP AI-07-001; CTN #124. A Study to

Evaluate the Use of a Protease Inhibitor and of **Interleukin-2 (IL-2)** in the Treatment of Early HIV Infection. Contact: Dr Brian Conway, Viridae Clinical Sciences / University of British Columbia, Vancouver, British Columbia, Canada
Tel: 604 689 9404

Study ID Numbers ESPRIT 001; 00 I-0071. A Randomized, Open-Label, Phase III, International Study of Subcutaneous Recombinant **IL-2** (Proleukin) in Patients with HIV-1 Infection and CD4+ Cell Counts Greater than or Equal to 300/mm³: Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT). Contact: Donald Abrams, Study Chair; David Cooper, Study Chair

Study ID Numbers 199/10325; COG-A0935A; CCG-0935; CCG-0935A. Monoclonal Antibody Therapy With **Sargramostim** and **Interleukin-2** in Treating Children With Neuroblastoma. Contact: Andrew L. Gilman, Chair Children's Oncology Group Tel: 816-234-3265

Study ID Numbers 199/14592; FHCRC-1365.00; NCI-G99-1622 **Interleukin-11** Plus **Filgrastim** Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors. Contact: Leona Holmberg, Fred Hutchinson Cancer Research Center, Seattle, WA
Tel: 206-667-6447

Study ID Numbers IL13-PEI-001; NCI-NABTT-9903; JHU-NABTT-9903 Interstitial Infusion of **IL13-PE38QQR Cytotoxin** in Recurrent Malignant Glioma. Contact: Stuart Grossman, M.D., Study Director The Johns Hopkins University, Baltimore, MD; Lewis Strauss, M.D.
Tel: 847-295-8678
Email: lstrauss@neophrm.com; Amy Grahn Tel: 847-295-8678
Email: agrahn@neophrm.com

Reviews of Interest

Brivanlou AH and Darnell, Jr. JE. Signal transduction and control of gene expression. *Science* 295:813, 2002.

Frucht DM. IL-23: a cytokine that acts on memory T cells. *Science STKE* 114:PE1, 2002.

Frucht DM, Fukao T, Bogdan C, Schindler H, O'Shea JJ and Koyasu S. IFN- γ production by antigen-presenting cells: mechanisms emerge. *Trends in Immunol.* 22:556, 2001.

Hjelmstrom P. Lymphoid neogenesis: de novo formation of lymphoid tissue in chronic inflammation through expression of homing chemokines. *J. Leuk. Biol.* 69:331, 2001.

Holloway AF, Roa S and Shannon MF. Regulation of cytokine gene transcription in the immune system. *Molec. Immunol.* 38:567, 2001.

Luster AD. The role of chemokines in linking innate and adaptive immunity. *Curr. Op. in Immunol.* 14:129, 2002.

Mogensen TH and Paludan SR. Molecular pathways in virus-induced cytokine production. *Micro. and Molec. Biol. Rev.* 65:131, 2001.

Montovani A, Locati M, Vecchi A, Sozzani S and Allavena P. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. *Trends in Immunol.* 22:328, 2001.

Murphy P, Baggiolini, M, Charo IF et al. International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. *Pharmacological Rev.* 52: 145, 2000.

Pestka, S. The human interferon alpha species and receptors. *Biopolymers* 55:254, 2000.

Roncarolo MG, Bacchetta R, Bordignon C, Narula S and Levings MK. Type 1 T regulatory cells. *Immunological Rev.* 182: 68, 2001.

Sims JE. IL-1 and IL-18 receptors, and their extended family. *Curr. Op. in Immunol.* 14:117, 2002.

Taniguchi T and Takaoka A. The interferon α/β system in antiviral responses: a multimodel machinery of gene regulation by the IRF family of transcription factors. *Curr. Op. in Immunol.* 14:111, 2002.

Trinchieri G. Regulatory role of T cells producing both Interferon γ and Interleukin 10 in persistent infection. *J. Exp. Med.* 194:F53, 2001.

Ye RD. Regulation of nuclear factor κ B activation by G-protein-coupled receptors. *J. Leuk. Biol.* 70:839, 2001.



Biology Tutors Needed
<http://www.tutoraid.org/>

Academic Assistance Access is a free tutoring service on the Web designed to offer assistance in the BIOLOGY field for students at both secondary and post secondary levels. If you are interested in sharing your knowledge with today's

youth why not join our tutor team. Help make a major contribution towards excellence in higher education.

For more information: George Richards, Academic Assistance Access

Biomedical Prestige Factor(c)
2001 Edition: Free Search Engine
http://www.prestigefactor.com/biomedical_search.mv

Review articles are 3 times more valuable than original-articles (3 times more citation rates), though they don't report new scientific insights based on the scientific method.

Unlike Impact Factor, we only take into consideration citations to original-articles. Thus our scores are not distorted.

Prestige Factor the true & fair value of Biomedical Journals solely based on scientific merit . 2,883 ranked Biomedical journals . 492 categories of journals (Therapeutics, Diagnostics, etc) No need to use our customer login. No registration required If you are using Netscape you will need version 6.0 or higher

3,000 Bio Protocols
www.orbigen.com

We list more than 3,000 bio protocols on our web site, full-text word search (not only abstracts) through most of the on-line journals, lists of links for all biology/biotech subjects and much, much more. No registration required, no fee!

Dictionary of Scientific Terms
www.pharma-lexicon.com

We have completed the largest database in the world of medical, pharma, biotech, dentistry, agrochem, veterinary and healthcare abbreviations (50,000). You can download the search box

and have it in your own computer (this is free). We also have a Palm Pilot (and pocket PC) version of this list. If you come across an abbreviation we have missed out we would love to hear from you.

InterProScan

<ftp://ftp.ebi.ac.uk/pub/databases/interpro/iproscan/>

This is to announce the release 3.1 of the stand-alone Perl-based InterProScan package satellite to InterPro Release Release 4.0 Tue Nov 6 2001.

InterPro is a collaborative project aimed at providing an integrated layer on top of the most commonly used protein signature databases by creating a unique, non-redundant characterization of a given protein family, domain or functional site. The InterPro project home page is available at <http://www.ebi.ac.uk/interpro/>.

InterProScan is a tool that allows to analyze a given protein sequence(s) against the InterPro signature databases (at the moment - PROSITE, PRINTS, Pfam, ProDom, Smart and TIGRFAMs).

InterProScan has a robust and efficient (parallel) architecture that could benefit from network distributed computing and support of UNIX queuing systems, such as LSF.

The updated InterPro related SRS parsers are available from <ftp://ftp.ebi.ac.uk/pub/databases/interpro/SRS/v4/>

Contact: InterHelp@ebi.ac.uk

What's new since v2.1

- * [Coiled-Coil search & display;]
- * [TMHMM search & display (not distributed);]
- * [SignalP search & display (not distributed);]
- * Interpro2GO parsing (+go);

- * converter.pl - shows GO in txt & html formats;
- * TIGRFAMs search;
- * TIGRFAMs family specific cut-offs (using TC)
- * scores parsing (+src);
- * implementation of PRINTS family specific cut-offs for FingerPRINTSscan;
- * 6 frame translation for nucleic acid sequence input.

Journal of Young Investigators www.jyi.org

A peer-reviewed journal for undergraduates JYI, Inc. is an exciting, student-led initiative to broaden the scope of the undergraduate scientific experience. JYI provides opportunities for students to participate in the scientific review and publication processes, primarily through the operation of its peer-reviewed journal for undergraduates. Incorporated as a non-profit, entirely student-run corporation, JYI's staff members currently represent over 30 different academic institutions. JYI has been featured in EurekaAlert!, Chemical Engineering News, and The Chronicle on Higher Education. Recently, an article highlighting JYI appeared in The New York Times (17 February 1999).


What is the web journal and what is its purpose?


JYI's web journal (which is also called JYI) is dedicated to the presentation of undergraduate research in science, mathematics, and engineering. It publishes the best submissions from undergraduates, with an emphasis on both the quality of research and the manner in which it is communicated. The journal, JYI, also allows students to experience the other side of the scientific publication process: the review process. Students working with their faculty advisors review the work of

their peers and determine whether that work is acceptable for publication in JYI.

How does JYI improve undergraduate science training?

If undergraduate education is to best prepare individuals for future participation in the scientific research community, then it clearly must include an introduction to the scientific research enterprise in its entirety. While many efforts to improve undergraduate science education are focusing on the important goal of making a student's experience more experiential and research-oriented, JYI is focusing on the rest of the problem: how to introduce students to the exercise of communicating their research, reviewing and being reviewed by peers, and other aspects of publishing and disseminating scientific information.


JYI focuses on providing this introduction to two groups of students - authors and editors. For student authors, JYI recognizes that they are likely to have little experience in scientific writing and in a peer-reviewed publication system. JYI therefore helps guide these students towards more effective scientific communication by encouraging them to publish their research and then helping them to develop their skills. Student editors - the other group of students - receive an in-depth experience in which they are trained as scientific reviewers and engaged in a dialog concerning the methods and future of scientific publishing. Recently, JYI's student editors gathered at the journal's annual editorial conference to discuss scientific publishing and participate in workshops lead by senior editors of Science Magazine. When these JYI authors and editors become professionals, they will be informed and experienced in issues concerning scientific publishing and will be effective communicators and reviewers. 



Top 10 reasons to come to the 2002 Joint Meeting of the ISICR/ICS/SLB/ECS in Torino!

(not counting the great Science to be presented)

- ❶ Holiday time in a beautiful city with an historical flair. Torino was the first capital of Italy and is considered to be one of the most important capitals of Baroque in Europe with more than two thousand years of history. Visit the Egyptian Museum, which is second in importance only to the one in Cairo.
- ❷ The Shroud of Turin! Claimed to be the body wrap of Jesus Christ after he was crucified. It is still being displayed in the Torino Cathedral. Be sure to call in advance or you won't get in!
- ❸ The piazzas. No, not pizzas. These are the beautiful squares and elegant boulevards that lend Torino its air of reserved majesty.
- ❹ Rekindle the flame in your romance (or, maybe start a new romance), or both. After all, you're in Italy!
- ❺ Put good use of the Italian course you took.
- ❻ The t in the acronym Fiat (Fabbrica Italiana Automobili Torino), which of course is located in Torino. The Museum of the Automobile is one of the world's great collections of antique cars, housed in a big, airy 1960 International Style building.
- ❼ Torino was as important to the birth of Italian filmmaking as to the Italian automobile industry. Checkout the eccentric Marionette Museum, or the long-shuttered Museum of Cinema. The annual Torino Film Festival is held here (although not during the meeting).
- ❽ Juventus FC - the best EVER Italian Football team. Two-time European Champions League, three-time UEFA Cup, two-time European Super Cup winners!
- ❾ Forget about Starbucks, drink first-rate coffee Italian style. Italy's largest coffee roaster, Lavazza, is headquartered in Torino.
- ❿ The French or Swiss Alps are within 1 hour or so driving time.

The city is also blessed with excellent wine and cheese, thanks to the surrounding hills and mountains of Piedmont. You could also try the famous FRITTO MISTO (leave your diet at home). Social gatherings at the IFN meeting will never be the same! 

2002 MEETING
ISICR/ICS/ECS/SLB
Lingotto Congress Center, Torino, Italy
October 6-11, 2002
<http://www.marionegri.it/cyto2002/>
E-mail: cyto2002@marionegri.it

Joint Meeting of the International Society for Interferon and Cytokine Research (ISICR), the International Cytokine Society (ICS), the European Cytokine Society (ECS) and Society for Leukocyte Biology (SLB)

ORGANIZING SECRETARIAT:

M.A.F. Servizi srl - Congress department
Via G.B. Vico 7 - 10128 Torino
Tel. +39 011 505 900 - Fax +39 011 505 976
www.mafservizi.it
E-mail: cyto2002@mafservizi.it

IMPORTANT DATES

❶ Abstract deadline: May 15, 2002

❷ Registration Fees (VAT included)

	<u>Before 30 May</u>	<u>After 30 May</u>
Member	Euro 700	Euro 800
Non-member	Euro 800	Euro 900
Students	Euro 350	Euro 400



Phrases in Italian you'll need to know!!!!

How much does this cost?

Quanto costa?

This costs too much!!

Costa troppo!!

This still costs too much!!!

Costa ancora troppo!!!!

I'm lost, can you help me find....

Mi sono persa (female), perso (male)
puo aiutarmi

Where is the nearest gelato shop?

Dov e' il negozio di gelati piu vicino?

Where is the nearest pastry shop?

Dov e' la pasticceria piu vicina?

Can I have ice in my water?

Posso avere del ghiaccio nell'a acqua?

Where is the nearest toilet?

Dov'e la "toilette" piu vicina (female),
Dov'e il bagno piu vicino (male)

Excuse me, Do you speak...

Mi scusi, parla.....

Will it rain today?

Oggi piovera'?

What will be the temperature today?

Quale sara la temperatura oggi?

Do you accept traveler's checks?

Accetta traveler's checks?

That was a wonderful dinner!!

E'stata una cena meravi gliosa!

Can I have some more wine?

Posso avere altro vino?

What was that food I just ate?

Che cos' e' quello che ho appena mangiato?

Where is the nearest chocolate shop?

Dov e' il negozio di cioccolata piu vicino?

Science Mystery:

Do YOU know
the Answer

?????

Many science books, illustrations, etc associate the word "EUREKA" with an important scientific discovery. Well, we know that ISICR members want to know: Where did this term come from? What is the origin of the association of this word with a scientific discovery? First correct answer (or an answer that sounds good because we don't know the correct answer) wins a cheap, I mean, valuable prize worth at least a 1.5 euros. Send your answer to any of the editors of this illustrious publication. Bribes might be accepted, especially if they are in the form of Italian chocolate.



**INTERNATIONAL SOCIETY FOR INTERFERON and
CYTOKINE RESEARCH**

9650 Rockville Pike
Bethesda, MD 20814-3998
U.S.A.

NON-PROFIT ORG.
U.S. POSTAGE
PAID
BETHESDA, MD 20814
PERMIT NO. 4982